Skip to main content
. 2011 Oct 17;102(12):2191–2198. doi: 10.1111/j.1349-7006.2011.02100.x

Figure 3.

Figure 3

 (A) Kaplan–Meier survival analysis of all 90 neuroblastoma (NB) patients stratified by negative and positive IMP3 expression. Patients with positive IMP3 expression had poor prognosis (P < 0.001, log–rank test). (B) Kaplan–Meier survival analysis of 64 NB patients with advanced disease (stages 3 and 4) showed a worse prognosis in patients with positive IMP3 expression than those with negative IMP3 (P = 0.005, log–rank test). (C) In 68 patients with normal MYCN status, patients with positive IMP3 expression showed a worse survival by Kaplan–Meier analysis (P = 0.001, log–rank test). (D) In 22 patients with MYCN amplification, patients with positive IMP3 expression also showed a worse survival by Kaplan–Meier analysis (P = 0.033, log–rank test).